VanEck Associates
ELOS

VanEck Associates’s Syneron Medical Ltd ELOS Stock Holding History

VanEck Associates’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-16,121
Closed -$166K – 740
2014
Q2 		$166K Buy
16,121
+2,939
+22% +$31.8K ﹤0.01% 630
2014
Q1 		$164K Buy
13,182
+2,735
+26% +$32.4K ﹤0.01% 604
2013
Q4 		$128K Buy
+10,447
New +$109K ﹤0.01% 594

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $480M AUM 32.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

VanEck Associates's ELOS Position: Q3 2014 in Review

VanEck Associates sold out of Syneron Medical Ltd (ELOS) in Q3 2014, closing a stake of 16,121 shares — an estimated $166K sold.

VanEck Associates first reported a position in ELOS in Q4 2013 and held it in 3 quarters. The position peaked at $166K in Q2 2014. 65 funds tracked by Wall St. Rank hold ELOS as of Q3 2014.

  • VanEck Associates reported no remaining Syneron Medical Ltd position as of Q3 2014 after selling out during the quarter.
  • VanEck Associates sold 16,121 Syneron Medical Ltd shares in Q3 2014, an estimated $166K.
  • VanEck Associates first reported a position in Syneron Medical Ltd in Q4 2013 and held it in 3 quarters.
  • VanEck Associates's Syneron Medical Ltd position peaked at $166K in Q2 2014.
  • 65 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2014.

Based on VanEck Associates's 13F filing for Q3 2014, filed 14 Nov 2014.